Recombinant human alkaline phosphatase (AMRIF/CEVEC)

N/A

Report date: 2022/07/19 16:22:54

Base Information

Drug NameRecombinant human alkaline phosphatase (AMRIF/CEVEC)
Drug Alias NameTheraptech projectRecombinant human placental alkaline phosphatasehRESCAPrhuAP-CAP cellrhuAP
ClassificationBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme
Mechanisms of ActionImmunomodulatorsCytokines modulators
TargetsCytokines
Therapy Area/IndicationsN/A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNetherlands
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAlloksys Life Sciences BvCevec Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAlloksys Life Sciences Bv
Active IndicationsN/A
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A